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ABSTRACT
Fracture risk is increased in type 1 diabetes (T1D). Diabetic neuropathymight contribute to this increased risk directly through effects on
bone turnover and indirectly through effects on balance, muscle strength, and gait. We compared patients with T1Dwith (T1DN+, n = 20)
and without (T1DN−, n = 20) distal symmetric sensorimotor polyneuropathy and controls (n = 20). We assessed areal bone mineral den-
sity (aBMD) and appendicular muscle mass by dual-energy X-ray absorptiometry, microarchitecture by high-resolution peripheral quan-
titative tomography at the standard ultra-distal site and at an exploratory 14% bone length site at the tibia and radius, bone turnover
markers, and muscle strength, gait, and balance by Short Physical Performance Battery (SPPB). At the standard ultra-distal site, tibial cor-
tical porosity was 56% higher in T1DN+ compared with T1DN− (p = .009) and correlated positively with the severity of neuropathy
(Toronto Clinical Neuropathy Score; r = 0.347, p = .028) and negatively with nerve conduction amplitude and velocity (r = −0.386,
p = .015 and r = −0.358, p = .025, respectively). Similar negative correlations were also observed at the radius (r = −0.484, p = .006 and
r = −0.446, p = .012, respectively). At the exploratory 14% offset site (less distal), we found higher trabecular volumetric BMD (tibia
25%, p = .024; radius 46%, p = .017), trabecular bone volume (tibia 25%, p = .023; radius 46%, p = .017), and trabecular number (tibia
22%, p = .014; radius 30%, p = .010) in T1DN– compared with controls. Both CTX and PINP were lower in participants with TD1 compared
with controls. No difference was found in aBMD and appendicular muscle mass. T1DN+ had worse performance in the SPPB compared
with T1DN– and control. In summary, neuropathy was associatedwith cortical porosity andworse performance in physical tests. Our find-
ings suggest that bone structure does not fully explain the rate of fractures in T1D.We conclude that the increase in the risk of fractures in
T1D is multifactorial with both skeletal and non-skeletal contributions. © 2021 The Authors. Journal of Bone and Mineral Research pub-
lished by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
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FORMANCE BATTERY
Introduction
D iabetes is a chronic disease characterized by hyperglyce-mia. In type 1 diabetes (T1D), the hyperglycemia is caused
by β-cells autoimmune destruction, leading to insulin defi-
ciency.(1) Juvenile onset is considered typical of T1D, but people
of any age can be affected and up to 50% of cases start in adult-
hood.(1) Most people living with T1D are adults.(1) Diabetic neurop-
athy is a result of nerve damage and leads to sensory
abnormalities.(2) Diabetic neuropathy can cause negative symp-
toms such as impaired touch, vibration, pinprick, hot and cold sen-
sation, or positive symptoms such as paradoxical pain and
hypersensitivity.(2)Distal symmetrical sensorimotor polyneuropathy
(DSPN) is themost common form of diabetic neuropathy and has a
stocking–glove distribution.(2)
Diabetes is a recognized risk factor for fractures.(3) A number
of meta-analyses have reported an increased risk of fractures in
people with diabetes.(4–10) The risk varies according to the type
of the disease and the skeletal site and is higher in people with
T1D. The most recent meta-analysis reported an almost fivefold
increase in the risk of hip fractures in T1D and a 33% increase
in type 2 diabetes (T2D).(10) Previous analysis found a 15%
decrease in the risk of wrist fractures and a 30% increase in the
risk of ankle fractures, but data camemainly from T2D patients.(9)
Data specifically on T1D reported a non-significant increase in
wrist fractures risk (hazard ratio [HR] = 1.78; 95% confidence
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interval [CI] 0.91–3.47) and an increase in ankle fractures
(HR = 2.56; 95% CI 1.41–4.61).(11)
The mechanisms for increased fracture risk are not fully estab-
lished, but it is likely to be multifactorial. Dual-energy X-ray
absorptiometry (DXA) can predict fractures in diabetes.(12) Over-
all, bone mineral density (BMD) is decreased in people with
T1D,(5) but the small decrease in BMD does not explain the mag-
nitude of the increase in the risk of fractures.(5) Several studies
have investigated bone microarchitecture in diabetes using
high-resolution peripheral quantitative computed tomography
(HR-pQCT).(13–19) Most of the studies have addressed T2D(14–20)
and data on T1D are scarce.(13) Results are conflicting, and the
most common finding was an increase in the cortical porosity
reported in T2D(14–18,20) but not in T1D.(13)
Some studies have reported differences in microarchitecture
associated with diabetic microvascular disease (MVD).(13,14)
Although neuronal regulation of bone metabolism has been
described,(21,22) no study has investigated the effect of diabetic
neuropathy on the skeleton. DSPN is a distal symmetrical predom-
inantly sensory neuropathy that affects up to 50% of patients with
diabetes.(23) The resulting sensory ataxia might also affect balance
and increase the risk of falling.(24–26) We investigated the effect of
T1D and diabetic neuropathy on the skeleton. We hypothesized
that neuropathy would be associated with cortical porosity and
poor physical performance in T1D. The aim of this study is to com-
pare bone structural and biochemical analysis, appendicular mus-
cle mass, and physical function test between adults with T1D
diabetes with and without DSPN and controls.
Materials and Methods
Participants and methods
This was a single-center, observational, cross-sectional, case-
controlled study to evaluate the effects T1D and diabetic neu-
ropathy on the skeleton in patients with T1D. White participants
with T1D were recruited from diabetes clinics and from research
participant lists in Sheffield (UK) between October 2017 and
October 2018. They were older than 18 years, had T1D for more
than 5 years, and estimated glomerular filtration rate (eGFR)
>60 mL/min/1.73m2. Healthy volunteers were recruited from
research participant lists or through emails sent to hospital staff.
Exclusion criteria were conditions that preclude analysis or inter-
pretation of scans; history of or current conditions known to
affect musculoskeletal health, diabetes, and/or neuropathy
assessment or bonemetabolism; the use of medications or treat-
ment known to affect musculoskeletal health, diabetes, and neu-
ropathy assessment or bone metabolism, including depot
medroxyprogesterone or the combined oral contraceptive pill;
alcohol intake greater than 21 units per week; high- or low-
trauma fracture less than 1 year before recruitment; and women
currently pregnant, trying to conceive, having delivered her last
child less than 1 year before recruitment, or in the perimeno-
pausal period including 5 years after menopause.
Neuropathy assessment
All subjects underwent detailed clinical and neurophysiological
assessments. The presence of DSPN was defined per Toronto
Diabetic Neuropathy Expert Group.(2) We used the Toronto Clin-
ical Neuropathy Score (TCNS) and nerve conduction assessment
by DPNCheck (Neurometrix, Waltham, MA, USA) to assess DSPN.
The TCNS assesses symptoms, reflexes, and sensory test at the
limbs.(2) Abnormalities are graded by scores to a maximum of
19. One examiner (TV) assessed symptoms (foot pain, numbness,
tingling, weakness, ataxia, and upper limb symptoms; present
1, absent 0), sensory tests (pinprick, temperature, light touch,
vibration, and position; abnormal 1, normal 0), and reflexes (knee
and ankle; absent 2, reduced 1, or normal 0). Patients were cate-
gorized according to the scoring as no neuropathy (0–5), mild
neuropathy (6–8), moderate neuropathy (9–12), and severe neu-
ropathy (>12). The TCNS has been validated against nerve con-
duction velocities and amplitudes(27) and morphological
criteria of sural nerve fiber density.(28)
Sural nerve conduction assessment was performed in both feet
using the validated DPNCheck device to confirm the presence of
DPN.(29) This is a point-of-care device that assesses nerve ampli-
tude potential (sural nerve action potential [μV]) and conduction
velocity (m/s) using principles similar to the standard nerve con-
duction studies.(30) DPNCheck has been validated and demon-
strated excellent reliability and acceptable accuracy in DSPN.
Participants with TCNS score ≤5 and normal nerve conduc-
tion assessment were considered without neuropathy (T1DN–;
n = 20), while participants with neuropathy (T1DN+; n = 20) were
defined by a combination of TCNS score >6 and abnormal nerve
conduction.(2) Individuals with HbA1c levels less than 5.7%
(39 mmol/mol)(31) were recruited as controls (n = 20). Groups
were matched by age, sex, height, and body mass index (BMI).
This study was approved by Liverpool Research Ethics Com-
mittee (IRAS 222726, 17/NW/0291). All participants provided
written informed consent, in accordance with Good Clinical Prac-
tice guidelines.
Areal BMD
DXA was used to measure whole body (coefficient of variation
[CV] = 1.3%), lumbar spine (CV = 1.6%), femoral neck (CV = 2.9%),
and total hip (CV = 1.5%) areal BMD (aBMD; Discovery A, Hologic
Inc., Bedford, MA, USA). Appendicular skeletal muscle mass was
determined by DXA and divided by squared height to calculate
the appendicular skeletal muscle mass index (ASMI).
HR-pQCT
We used HR-pQCT by XtremeCT I (Scanco Medical AG, Brüttisel-
len, Switzerland) to assess bone geometry, volumetric BMD
(vBMD), microarchitecture, and estimated bone strength at the
nondominant radius and tibia in all participants.
Standard ultra-distal site
Image acquisition, analysis, and validation of the method for the
standard ultra-distal sitewas performed as previously described.(32)
In summary, the first image was obtained at 9.5 and 22.5 mm from
a line placed at the inflection point on the endplate of the distal
radius or tibial plafond, respectively(33) (Figs. 1A and 2A).
Exploratory 14% offset site
An additional exploratory site, located at 14% of the bone length
(exploratory 14% offset site) was also scanned (Figs. 1A and 2A)
to further investigate the cortical compartment since previous
literature reported findings in cortical porosity in diabetes. One
examiner (MP) measured the limb length; for the radius length,
with the forearm flexed to 90, we measured from the tip of
the olecranon to the radial styloid process, and for the tibia, with
the knee at 90 , we measured from the medial condyle to the
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Fig 1. (A) Radius scout view scan with reference lines (solid) and the volume of interest (VOI; between two broken lines). In white is the standard ultra-
distal site with reference line placed at the inflection point on the endplate of the distal radius plafond. In green, the reference line is placed at the distal
end of the radius and the VOI starting at the 14% radius length previously calculated and manually inserted. (B) 3D image of the standard ultra-distal
radius. (C) 3D image of the exploratory14% offset site showing a thick cortex and abundant trabecular bone.
Fig 2. (A) Tibia scout view scan with reference lines (solid) and the volume of interest (VOI; between two broken lines). In white is the standard ultra-distal
site with reference line placed at the inflection point on the endplate of the distal tibia plafond. In green, the reference line is placed at the distal end of the
tibia and the VOI starting at the 14% tibia length previously calculated and manually inserted. (B) 3D image of the standard ultra-distal tibia. (C) 3D image
of the exploratory 14% offset site showing a thick cortex and abundant trabecular bone.
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medial malleolus to the nearest 0.1 cm using a tape measure.
Each participant’s radius and tibia 14% length were calculated
and inserted in the relative position to scout view reference
line, ensuring that the first slice of the measurement was
acquired 1 mm proximal to the 14% site. The scan was then
precalibrated before the participant’s limb was positioned
within the scanner. At all sites, a total of 110 cross-sectional
images were obtained, corresponding to 3D representation of
9.02-mm-thick cross sections with an isotropic image voxel size
of 82 μm. To assess the quality of the images, we used the visual
grading system reported by Engelke and colleagues.(34) In brief,
the quality of each scan image was categorized as either per-
fect (G1) or showing a slight (G2), moderate (G3), or unaccept-
able (G4) degree of movement artifact. Images G4 were
excluded from the analysis.
HR-pQCT image segmentation and analysis were performed
using the standard built-in software (version 6.0, Scanco Medi-
cal). We analyzed trabecular variables (trabecular bone volume
fraction [BV/TV], number [Tb.N], thickness [Tb.Th], and separation
[Tb.Sp]) as described.(35) For the standard ultra-distal site, preci-
sion errors were calculated in accordance with the International
Society for Clinical Densitometry recommendations.(36) In our
center, smaller precision errors were observed for densitometric
(CV = 0.2–5.5%) than for microstructural (CV = 1.2–7.0%),
extended cortical bone (CV = 3.4–20.3%), and biomechanical
(CV = 0.3–9.9%) measures at both the radius and tibia.(32)
We used Image Processing Language (IPL v5.08b) provided by
the manufacturer (Scanco Medical AG) for cortical variables anal-
ysis. Contours that delineated bone from soft tissue and trabec-
ular from cortical bone were automatically placed and
manually corrected if needed to define cortical compartment.
Cortical bone volume, cortical vBMD, and cortical area weremea-
sured, and cortical porosity was calculated.(37,38) We analyzed
trabecular and cortical variables at both sites. Micro–finite ele-
ment analysis was used to estimate biomechanical parameters
at standard ultra-distal and exploratory 14% offset sites at the
radius and tibia (version 1.13; FE-solver included in the Image
Processing Language, Scanco Medical AG, Zurich, Switzerland).
We applied micro–finite element analysis (version 1.13;
Scanco Medical AG) to the HR-pQCT images to assess bone bio-
mechanical properties. We obtained measures of stiffness and
ultimate failure load. The model parameters were set as: material
properties isotropic and elastic, cortical bone Young’s modulus
20 GPa, trabecular bone Young’s modulus 17 GPa, Poisson’s ratio
0.3. The proximal end of the section was fixed and a compression
strain of 1% was applied to the distal surface of the section.(39)
BTM
Fasting blood samples were collected between 8:00 and
10:00 a.m., processed, and the serum was stored at −80 until
analysis. Carboxy-terminal cross-linking telopeptides of type I
collagen (CTX) and N-terminal propeptide of type I collagen
(PINP) were measured in serum in a single batch using the IDS-
iSYS multidisciplined automated chemiluminescence immuno-
assay (Immunodiagnostic Systems, Boldon, UK). The interassay
CVs were 6.5% for CTX and 7.2% for intact PINP, as previously
published from our center.(40)
Physical performance test
The Short Physical Performance Battery (SPPB) assesses balance,
lower extremity strength, and gait.(41) Participants were asked to
stand with their feet side-by-side, in semi-tandem and tandem, to
evaluate standing balance, to stand up and sit down five times as
quickly as possible, and to “walk at their usual speed” on an
8-foot walking course. Each of these three objective measures is
scored from 0 to 4, with higher scores indicating greater physical
function.
Handgrip strength was measured three times in each side
using a digital hand dynamometer (Seahan Corp., Masan, South
Korea). The maximal grip strength was used for analysis.
Statistical analysis
Because cortical porosity was the main microarchitectural fea-
ture affected in diabetes in previous studies, we used the differ-
ence in cortical porosity previously reported between patients
with diabetes with and without fractures (3.86% ± 1.30 versus
0.83 ± 0.13, respectively)(20) as the clinically significant differ-
ence. This resulted in a sample size of 20 in each group. This sam-
ple size has 80% power to detect a difference of 3.0% in cortical
porosity at p < .05.
Variables are described as mean and standard deviation
(normally distributed) or median and interquartile range (non-
normally distributed). Normally distributed variables were
compared using ANOVA followed by Scheffe post hoc test. Non-
normally distributed variables were compared using the Kruskal–
Wallis test. For these analyses, a p < .05was considered significant.
For non-normally distributed variables, the Mann–Whitney test
was used for pairwise comparison with the Bonferroni correction
for multiple comparison, resulting in a p < .017 as significant.
In the participants with T1D, the relationship between markers
of nerve conduction assessment and DXA and HR-pQCT features
were assessed using Spearman’s rank correlation (non-normally
distributed). The analyses were performed using IBM SPSS Statis-
tics for Mac (version 25.0, IBM Corp., Armonk, NY, USA).
Results
Seventy-one potential participants were screened for this study,
10 were excluded according to inclusion and exclusion criteria,
and 1 participant withdrew after the screening visit. Sixty partici-
pants were recruited: 20 participants T1DN+, 20 T1DN–, and 20
healthy controls (control). Table 1 shows the characteristics of
the 60 participants. As expected, HbA1c was higher in diabetics
compared with controls. Among the diabetic group, there was
no difference in diabetes duration between the groups (T1DN+
28.9 years ±10.6 and T1DN– 24.6 years ±15.5). Participants with
T1D had had more fractures than participants without diabetes.
In T1D patients, the mean age at diagnosis was 22.2 ± 12.0 years
and the duration of disease ranged from 6 to 58 years (mean
26.5 ± 13.1 years). We used the mean HbA1c from clinical records
(5 to 10 years) to estimate metabolic control (mean HbA1c), and it
was worse in T1DN+ than T1DN– (Table 1). In 16 (40%) of the T1D
patients, diabetes onset was before 20 years old.
DXA
aBMD measured by DXA at the femoral neck (FN), total hip (TH),
and lumbar spine (LS; L1 to L4) was not different between the
groups (Table 1). In the diabetic groups, FN and TH BMD corre-
lated positively with nerve conduction velocity (r = 0.481,
p = .002 and r = 0.388, p = .015, respectively). ASMI was not differ-
ent between the three groups (Table 1).
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HR-pQCT results
All the participants were assessed at the wrist and ankle. Nine stan-
dard ultra-distal site radial scans were excluded because of move-
ment artifacts (4 T1DN+, 4 T1DN–, and 1 control). Twenty-one
exploratory 14%offset radius site scanswere not available because
of technical issues (movement artifact or the exploratory 14% off-
set site was out of the scanning area), namely 8 in the T1DN+
group, 7 in the T1DN– group, and 6 in the control group. One
Table 1. Study Population Characteristics, Neuropathy Assessment, DXA, Bone Turnover Markers, and Physical Tests Outcomes Reported
asMean (Standard Deviation) for Normally Distributed Variables andMedian (Interquartile Range) for Non-normally Distributed Variables
T1DN+ (n = 20) T1DN– (n = 20) Control (n = 20) p Value
Age (years) 47.7 (11.0) 49.6 (13.1) 49.1 (12.5) .872
Height (cm) 172.6 (8.2) 171.4 (10.3) 170.6 (9.7) .792
Weight (kg) 77.6 (18.4) 72.9 (12.0) 71.4 (10.7) .358
BMI (kg/m2) 25.9 (5.2) 24.8 (3.6) 24.4 (2.5) .486
Tibia length (mm) 396.3 (25.7) 388.5 (29.5) 387.0 (30.1) .549
Radius length (mm) 280.0 (21.9) 276.0 (23.0) 277.5 (21.1) .850
HbA1c (mmol/mol) 70.2 (14.3) 62.5 (14.6) 34.7 (3.2) <.001
Mean HbA1c (mmol/mol) 77.1 (17.5) 64.4 (11.4) NA .01
Diabetes duration (years) 28.9 (10.6) 24.1 (15.3) NA .108
TCNS 13.3 (5.7) 2.5 (1.7) NA <.001
DPNCheck conduction velocity 32.1 (17.9) 48.4 (4.2) NA <.001
DPNCheck amplitude 3.6 (2.3) 11.7 (6.3) NA <.001
Sex (female) 8 8 8
Previous fractures (n) 13 10 5 .038
Falls in the last 6 months (n) 2 2 3 .851
Smoking (current/ex) 2/5 1/3 1/9 .269
LS T-score −0.3 (−1.7, 0.5) −0.7 (−1.7, 0.1) −0.8 (−2.0, −0.2) .597
FN T-score −1.2 (−2.0, −0.5) −0.7 (−1.5, 0.0) −1.2 (−1.6, −0.6) .181
TH T-score −0.5 (−0.9, 0.2) −0.2 (−0.7, 0.6) −0.6 (−1.1, 0.0) .423
ASMI (kg/h2) 7.4 (1.3) 7.6 (1.2) 7.4 (1.4) .853
PINP (ng/mL) 41.9 (29.4, 50.2) 38.1 (31.8, 51.2) 58.0 (47.1, 79.5) .013
CTX-I (ng/mL) .037 (0.033, 0.102) .047 (0.033, 0.115) .357 (0.039, 0.641) .014
SPPB (score) 10.3 (2.1) 11.8 (0.4) 11.9 (0.4) <.001
Hand grip (Kg) 28.5 (20.6–33.9) 28.4 (21.1–40.8) 35.1 (20.9–42.6) .418
BMI = bodymass index; HbA1c = hemoglobin A1c or glycosylated hemoglobin; TCNS = Toronto Clinical Neuropathy Score; LS = lumbar spine; FN = fem-
oral neck; TH = total hip; ASMI = Appendicular Skeletal Muscle Mass Index; SPPB = Short Physical Performance Battery.
Fig 3. (A) Box and whisker plot of cortical porosity (%) at tibia and radius at standard ultra-distal site. (B) Correlation Co.Po (%) and nerve amplitude (μV) at
the tibia (r = −0.386; p = .015) and (C) radius (r = −0.484; p = .006).
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Table 2. Tibia and Radius Geometry, BMD, Microarchitecture and Estimate Biomechanical Parameters at the Standard Ultra-Distal Site Data Given as Mean (SD) or Median (IQR)
Tibia Radius
T1DN+ (n = 20) T1DN– (n = 20) Control (n = 20)
p




Total area (mm2) 835 (152) 771 (119) 766 (144) .227 358 (67.9) 343 (86.2) 338 (88.1) .765
Trabecular area (mm2) 697 (151) 627 (100) 627 (130) .151 288 (62) 273 (77.3) 273 (80.4) .81




296 (57.7) 318 (61.7) 303 (36.9) .422 311 (60.9) 322 (64.6) 307 (50.5) .737
Tb.vBMD
(mg HA/cm3)
182 (44.6) 188 (40.8) 172 (29.2) .456 171 (52.6) 171 (37.1) 168 (36.5) .968
Ct.vBMD
(mg HA/cm3)
845 (817–895) 901 (861–929) 892 (833–916) .106 873.8 (842.4–895.8) 876.8 (850.4–904.8) 872.6 (816.2–895.2) .577
Microarchitecture
Tb.BV/TVd .152 (0.037) .156 (0.034) .144 (0.025) .457 .143 (0.044) .143 (0.031) .140 (0.030) .969
Tb.N (1/mm) 1.96 (0.44) 1.95 (0.33) 1.8 (0.25) .300 1.91 (0.33) 1.97 (0.27) 1.99 (0.25) .716
Tb.Th (mm)d .078 (0.014) .080 (0.011) .080 (0.008) .805 .074 (0.016) .072 (0.011) .070 (0.011) .629
Tb.Sp (mm)d .409 (0.367, 0.528) .448 (0.373, 0.505) .494 (0.431, 0.540) .288 .446 (0.384, 0.491) .424 (0.389, 0.479) .420 (0.399, 0.472) .814
Ct.Th (mm)d 1.16 (0.31) 1.23 (0.39) 1.24 (0.21) .660 .78 (0.18) .81 (0.19) .72 (0.16) .334
Ct.Po (%)d 7.48 (5.19, 9.48) 4.8 (3.1, 6.64)a 5.81 (4.14, 7.36) .028 2.52 (1.58, 3.18) 1.56 (0.94, 1.94) 1.98 (1.2, 2.86) .069
Estimated biomechanical
parameters
Stiffness (kN/mm) 244 (58.5) 250 (67.9) 235 (54.4) .749 98.9 (29.2) 96.6 (26.8) 88.7 (27.7) .523
Failure load (kN) 12.3 (3) 12.5 (3.3) 11.8 (2.7) .730 5 (1.5) 4.9 (1.3) 4.5 (1.4) .571
Tb.vBMD = trabecular volumetric bonemineral density; Ct.vBMD = cortical volumetric bonemineral density; Tb.BV/TV = trabecular bone volume fraction; Tb.N = trabecular number; Tb.Th = trabecular thickness;
Tb.Sp = trabecular separation; Ct.Th = cortical thickness; Ct.Po = cortical porosity.
aT1DN– compared with T1DN+, p = 0.009.
dDerived measurement method(33).





































































Table 3. Tibia and Radius Geometry, BMD, Microarchitecture, and Estimate Biomechanical Parameters at Exploratory 14% Offset Site Data Given as Mean (SD) or Median (IQR)
Tibia Radius
Exploratory 14% offset site T1DN+ (n = 20) T1DN– (n = 20) Control (n = 19)
p




Total area (mm2) 559 (487, 642) 522 (470, 555) 544 (454, 595) .438 534.3 (86) 531.2 (70.6) 502.2 (68.7) .477
Trabecular area (mm2) 380 (84.9) 344 (64.2) 348 (57.3) .218 89.9 (25.5) 81 (22.9) 80.7 (27) .573




414 (66.6) 437 (91.8) 419 (49.7) .560 576.9 (539.4, 617.7) 589.0 (562.9, 690.4) 598.9 (541.4, 634.6) .463
Tb.vBMD
(mg HA/cm3)
143 (39.3) 143 (33)b 118 (24.7) .015 140.8 (50.6) 148.2 (41.2)c 101.3 (27.3) .009
Ct.vBMD
(mg HA/cm3)
987 (958, 1003) 1001 (965, 1019) 1006 (962, 1021) .529 1042.5 (1027.5, 1080.9) 1061.0 (1039.4, 1072.8) 1057.5 (1031.3, 1073.6) .962
Microarchitecture
Tb BV/TVdd .119 (0.033) .124 (0.027)b .099 (0.021) .015 .117 (0.042) .123 (0.034)c .084 (0.023) .009
Tb.N (1/mm) 1.70 (0.41) 1.79 (0.33)b 1.47 (0.19) .010 1.53 (0.41) 1.7 (0.25)b 1.31 (0.25) .009
Tb.Th (mm)d .071 (0.014) .070 (0.013) .067 (0.010) .631 .077 (0.017) .072 (0.015) .064 (0.013) .122
Tb.Sp (mm)d .49 (0.45, 0.70) .51 (0.42, 0.61)b .60 (0.57, 0.66) .032 .59 (0.50, 0.86) .50 (0.47, 0.60)c .65 (0.58, 0.92) .008
Ct.Th (mm)d 1.94 (0.30) 2.01 (0.47) 2.01 (0.25) .808 1.58 (0.18) 1.64 (0.23) 1.57 (0.2) .632




Stiffness (kN/mm) 240.2 (43.3) 239.8 (58.7) 233.4 (42.3) .886 100 (13.8) 99.1 (24.2) 95.0 (21.5) .784
Failure load (kN) 12 (2.2) 11.9 (2.9) 11.6 (2.1) .889 5.0 (0.7) 4.9 (1.2) 4.7 (1.1) .794
Tb.vBMD = trabecular volumetric bonemineral density; Ct.vBMD = cortical volumetric bonemineral density; Tb.BV/TV = trabecular bone volume fraction; Tb.N = trabecular number; Tb.Th = trabecular thickness;
Tb.Sp = trabecular separation; Ct.Th = cortical thickness; Ct.Po = cortical porosity.
bT1DN– compared with controls Tb.vBMD Tibia p =.024 Radius p =.017; Tb.BV/TV Tibia p =.023 Radius 0.017; Tb.N Tibia p =.014 Radius p=.010; Tb.Sp Tibia p=.015 Radius 0.001.
For Tb.SP, non-parametric test was used (p < .017).
dDerived measurement method(33).







































exploratory 14% offset site at the tibia (control) was not included
because of movement artifacts.
At the standard ultra-distal site, tibial cortical porosity was
56% higher in T1DN+ compared with T1DN– (p = .009) (Fig. 3)
and tended to be higher in T1DN+ compared with controls,
but it did not reach statistical significance. There was also a trend
to similar results at the radius (Fig. 3). Because cortical porosity is
highly sensitive to reduced image quality, we reran the analysis
including only high-quality images (grades 1 and 2) and found
similar results. There were no other significant differences
among the three groups at the radius or tibia (Table 2). Tibia total
and cortical density and cortical TMD correlated positively with
nerve conduction velocity (r = 0.416, p = .008; r = 0.408, p = .01;
and r = 0.365, p = .022, respectively). Cortical porosity correlated
negatively both with nerve conduction velocity and amplitude at
the tibia (r = −0.358, p = .025 and r = −0.386, p = .015, respec-
tively) and radius (r = −0.446, p = .012 and r = −0.484, p = .006)
(Fig. 3). At the tibia, cortical porosity also correlated positively
with TCNS (r = 0.347, p = .028).
At the exploratory 14% offset site, we found favorable trabec-
ular microarchitecture when comparing T1DN– and control both
at the radius and tibia in a consistent pattern (Table 3, Fig. 4). We
found higher trabecular volumetric BMD (Tb.vBMD; 46% higher
at the radius, p = .017; 25% higher at the tibia, p = .024) and tra-
becular number (Tb.N; 30% higher at the radius, p = .010; 22%
higher at the tibia, p = .014). Trabecular thickness was not differ-
ent between the groups (Fig. 4). There was a trend for T1DN+ to
follow the same pattern, but it did not reach statistical signifi-
cance. No significant differences in any HR-pQCT parameters at
the exploratory 14% offset site were found between diabetic
groups. There were no differences in cortical features or esti-
mated biomechanical parameters among the three groups at
the exploratory 14% offset site.
BTM results
PINP and CTX were lower in both T1DN+ and T1DN– compared
with controls. PINP was 34% (p = .006) and 28% (non-significant)
lower in T1DN– and T1DN+ compared with controls, whereas
CTX was 87% (p = .016) and 90% (p = .011) lower, respectively
(Fig. 5). No difference was found between diabetic groups
(T1DN+ and T1DN–).
Physical performance
T1DN+ participants had worse performance in the SPPB but not
at the handgrip test than T1DN– and healthy controls (Table 1).
Four of 20 T1DN+ had poor performance according to the
revised European consensus on definition and diagnosis of
Fig 4. Box and whisker plot of (A) trabecular volumetric BMD (Tb.vBMD), (B) trabecular bone volume (BV/TV), (C) trabecular number (Tb.N), and (D)
trabecular thickness (Tb.Th) at radius and tibia at 14% site.
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sarcopenia.(42) T1DN– performance was similar to the control
group. ASMI was not different between the groups (Table 1).
Discussion
This is the first study to investigate the effect of DPSN on the skel-
eton in T1D. Cortical porosity was higher in T1DN+ compared
with T1DN– at the tibia standard ultra-distal site. Cortical porosity
at the tibia correlated positively with TCNS and negatively (both
at the radius and tibia) with nerve conduction amplitude and
velocity. Conversely, total and cortical tibia density and TMD cor-
related positively with nerve conduction velocity. At the explor-
atory 14% offset site (less distal), we found favorable trabecular
microarchitecture, both at the radius and the tibia in T1DN– in
a consistent pattern. There was a trend toward the same pattern
in T1DN+. We found low bone turnover as both CTX (T1DN+ and
T1DN–) and PINP (T1DN–) were lower in participants with diabe-
tes comparedwith controls. aBMDmeasured by DXAwas not dif-
ferent between the three groups, but proximal femur BMD was
positively correlated to nerve conduction velocity in the diabetic
groups. Despite no difference in ASMI, T1DN+ had worse perfor-
mance in the SPPB but not in handgrip strength compared with
T1DN– and control.
Our findings suggest that neuropathy is associated with
increased cortical porosity. There is ex vivo and clinical evidence
for a neuronal control of bone remodeling.(21,22) Recently, a his-
tomorphometry study in humans with high bone turnover
showed clear anatomical association of nerves and bone remo-
deling surfaces and a high density of nerve profiles in intracorti-
cal pores. The authors claim that this anatomical link between
innervation and bone remodeling sites suggested a role for
innervation in bone remodeling.(22) In participants with T1D,
we found negative correlations between nerve conduction
amplitude and velocity and cortical porosity at the tibia and
radius. In addition, TCNS correlated positively with tibial cortical
porosity, suggesting that more severe neuropathy is associated
with higher cortical porosity. We also found positive correlations
between proximal aBMD (both FN and TH), and peripheral total
and cortical vBMD at the tibia and nerve conduction velocity.
Taken together, these findings suggest a positive association of
nerve function on cortical bone density.
We found low bone turnover and preserved trabeculae in T1D,
and these findings might be linked. A number of studies have
reported low bone turnover associated with both T1D and
T2D,(13,14,43) suggesting a role for hyperglycemia. In vitro studies
have shown that chronic hyperglycemia inhibits osteoclast(44)
and osteoblast differentiation and activity.(45) The glucose can
also bind to proteins, leading to the formation of advanced gly-
cation end products (AGEs). Hyperglycemia promotes the forma-
tion of AGEs, especially in long-lived tissue proteins such as
collagen. In vitro studies have shown that AGEs also decrease
osteoclast differentiation and activity and osteoblast activ-
ity.(46,47) Therefore, there is evidence for both direct and indirect
effects of hyperglycemia in the skeleton. Shanbhogue and col-
leagues also reported lower BTM in T1D but, in contrast to our
study, they reported lower vBMD (lower total and trabecular
BMD and lower trabecular thickness at radius and tibia) and
lower estimated biomechanical parameters when comparing
T1D participants with and without MVD.(13) Noteworthily, the
study design was different; the groups were not matched and
there was a sex imbalance, withmoremales in the groupwithout
MVD. In addition, they reported the data for overall MVD, while
we focused on neuropathy.
Limitations of the HR-pQCT method could contribute to the
inconsistent findings at the standard ultra-distal and exploratory
14% offset sites. Although we report favorable microarchitecture
at the tibia and radius at the exploratory 14% offset site for
T1DN–, we did not find the same pattern at the standard
ultra-distal site. Shanbhogue and colleagues have reported that
variation in bone length introduces a systematic error in the esti-
mation of some HR-pQCT–derived bone variables such as trabec-
ular number.(48) We speculate that these errors could have
influenced our results at the standard ultra-distal site. In addition,
we reported increased cortical porosity at the standard ultra-dis-
tal site in the T1DN+ group but not at the exploratory 14% offset
site. Two features might have influenced these findings. First,
cortical porosity was lower at the exploratory 14% offset site;
median 1.51–2.48% at the exploratory 14% offset site compared
with 4.8–7.48% at the standard ultra-distal site at the tibia, and
Fig 5. Box and whisker plot of PINP (A) and CTX (B) in the three groups.
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0.41–0.56% and 1.56–2.52%, respectively, at the radius. It is pos-
sible that at the exploratory 14% offset site, most of the pores
were below the threshold of detection. In addition, we claim that
neuropathy might also have influenced the results. Because
peripheral neuropathy is a length-dependent process, we specu-
late that its effects would be more evident more distally.
Previous studies have also reported inconsistent results in
microarchitecture in diabetes.(13–18) In the cortical compartment,
both increase(14,16,17,20) and decrease(11,15) in cortical porosity
have been previously reported in T2D. Our cortical findings
agree with previous data that reported an increase in cortical
porosity in T2D at the standard ultra-distal site.(16–18) Although
Shanbhogue and colleagues reported higher cortical porosity
in T2D with MVD,(14) in de Waard and colleagues, the presence
of MVD was not associated with any bone parameters.(15) The
previous study in T1D found no differences in cortical poros-
ity.(13) In the trabecular compartment, most studies in T2D
reported no findings, while two cohorts reported favorable find-
ings.(15,19) A cohort of 954 elderly women, including 99 with T2D,
60% of themwith early disease, showed that T2D was associated
with favorable trabecular microarchitecture at the standard
ultra-distal site, in a similar pattern to what we found at the
exploratory 14% offset site, with higher trabecular BV/TV and tra-
becular number.(19) In addition, data from The Maastricht Study
including 410 (radius) and 198 (tibia) participants of mean age
58 years, 51% of females reported higher Tb.N both at the radius
and tibia and no influence of MVD.(15) In T1D, unfavorable trabec-
ular findings were reported when comparing participants with
andwithout MVD, as mentioned above. Our results at the explor-
atory 14% offset site are similar to the favorable findings in T2D
at the standard ultra-distal site in bigger cohorts. In contrast with
the previous study in T1D, we found no differences between the
diabetic groups, either at the standard ultra-distal or the explor-
atory 14% offset site.
Favorable trabecular findings have also been reported in his-
tomorphometry in T2D.(49) Recently, Andrade and colleagues
compared histomorphometry in premenopausal T2D women
with good (n = 10, HbA1c < 7%) and poor metabolic control
(n = 16, HbA1c > 7%) to age- and race-matched controls without
diabetes.(49) The authors reported greater BV/TV in T2D with
good control compared with the non-diabetic control group
and borderline findings in the poor control group (p = .05). Fur-
thermore, there was greater Tb.N and lower trabecular separa-
tion in both T2D groups compared with non-diabetics
regardless of the metabolic control. There was a negative corre-
lation between HbA1c and features of osteoid function, such as
osteoid thickness and osteoid surface.(49) These findings sug-
gested that mild hyperglycemia was associated with preserved
trabecular structure and reduced bone formation, similarly to
our findings in T1DN-.
Interestingly, although significant differences were found on
cortical porosity at the standard ultra-distal site and on trabecu-
lar compartment at the exploratory 14% offset site, there were
no differences in FE results. We speculate that the differences
found in each compartment were not big enough to result in sig-
nificant differences in biomechanical parameters. Furthermore, it
is important to consider that we have used standard material
properties for the FE calculation, and it is possible that bone
material properties could be altered in diabetes.(50,51)
The risk of fractures is increased in T1D and despite the
increased cortical porosity in T1DN+, the favorable trabecular
findings in T1DN– might seem like a paradox. This paradox sug-
gests a role for non-skeletal features on this increased risk. The
vast majority of the non-spine fractures are attributed to falls.(52)
There is evidence that hypoglycemia and neuropathy increase
the risk of falls.(53,54) Older women with diabetes have an
increased risk of falls and the risk is higher in insulin users.(55)
Shah and colleagues investigated falls in T1D and reported a
high frequency among middle-aged and older adults with
T1D.(54) Severe hypoglycemia was associated with a threefold
increase in the risk of falls and peripheral neuropathy with a two-
fold increase in this risk. The presence of neuropathy and trip-
ping over an uneven surface were the most common factor
related to falls reported by participants.(54) In our study, T1DN+
had worse performance in SPPB. This test battery assesses bal-
ance, gait, and lower limb strength(41) and was associated with
an increased risk of falls.(56) Balance and gait are complex tasks.
Information received from the vestibular, visual, and somatosen-
sory systems are combined and the final control is mediated
through the motor system.(57) Neuropathy might negatively
affect the somatosensory and motor systems and increase the
risk of falls. Cohort studies have shown worse physical perfor-
mance in elderly people with diabetes, partially mediated by a
decrease in peripheral nerve function.(19,25,26)
In addition, muscle function can also be affected in diabetes. T1D
children with poor glycemic control had lower grip strength than
non-diabetic children.(58) In adolescents, dynamic muscle function
evaluated by jumping mechanography showed lower relative mus-
cle power and force in T1D compared with the reference.(59) A Jap-
anese study assessed participants with T1D (42 to 75 years) without
severe neuropathy and reported poor performance, compatible
with sarcopenia according to the AsianWorking Group for Sarcope-
nia criteria, including lower muscle mass and handgrip and lower
limb strength.(60) We found no difference on ASMI or physical test
performance between T1DN– and controls, but T1DN+ participants
had worse performance at SPPB. In addition, 4 T1DN+ participants
had poor performance on physical tests, suggesting sarcopenia.
Therefore, neuropathywas associatedwithworse lower limbmuscle
function despite no difference inmusclemass, suggesting an impor-
tant role for ataxia and muscle weakness.
We found no differences in aBMDbetween the groups. Data in
aBMD in T1D is conflicting,(5,61) but a meta-analysis reported a
decrease in aBMD.(5) We speculate that our sample size was too
small to detect any difference, especially between groups
matched for weight.
This study has limitations. We were not able to match partici-
pants individually to important confounders such as age, height,
and bodymass index, but there were no differences between the
groups. We used a point-of-care device to assess nerve conduc-
tion, but it has been previously validated against the gold stan-
dard method.(62) We assessed only the sural nerve, whereas,
ideally, nerve conduction studies should test multiple nerves to
confirm polyneuropathy; however, clinical features were also
assessed by the TCNS. We included an exploratory 14% bone
length site that has not been validated, but other less distal sites
have been previously described,(19,20) and the analysis showed
interesting results. At the exploratory 14% offset site, cortical
bone is thicker and therefore more susceptible to the effect of
beam hardening. We did not assess bone material properties.
We used SPPB to assess muscle function, and the test provides
limited detail in the contribution of somatosensory and motor
function in the physical function performance. We assessed par-
ticipants with T1D. Because diabetic neuropathy also affects T2D,
we speculate that similar associations between neural dysfunc-
tion and skeletal features could affect this population, but further
studies should be done to investigate T2D.
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In summary, we report an increase in cortical porosity associ-
ated with DSPN but favorable trabecular microarchitecture in
T1DN–. We speculate that nerve dysfunction and low bone turn-
over have influenced these results. We did not assess bonemate-
rial properties, but our findings suggest that bone structure
contributes but does not fully explain the higher fracture risk in
T1D. In addition, T1DN+ had worse performance in tests that
assess not only muscle strength but also balance and gait. Our
findings suggest that the increase in the risk of fractures in T1D
is multifactorial and both skeletal and non-skeletal features are
involved.
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